PITTSBURGH, Jan. 15, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) will host its second quarter fiscal year 2025 earnings call on Wednesday, February 5, 2025. The press release and presentation will be available on the Company's website before market on February 5.  Details of the conference call and webcast are as follows: When: Wednesday, February 5, 2025, at 9:30 am ET Hosts: Sanjay Chowbey, President and CEOPatrick Watson, Vice President and CFO Webcast:  The conference call ...

PITTSBURGH, Jan. 15, 2025 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that Faisal Hamadi, currently Vice President of Kennametal's Value Creation Systems, will succeed Franklin Cardenas as President of the Company's Infrastructure segment, effective January 20, 2025."I want to thank Franklin for his years of service and many contributions to Kennametal," said Sanjay Chowbey, President and CEO. "We wish him success in his future endeavors and appreciate his ongoing partnership with Faisal to ...

Kennametal Inc. (KMT) has been benefiting from strength in the Infrastructure segment, driven by solid momentum in the aerospace & defense and energy end markets arising from favorable order timing. The segment’s revenues inched up 0.4% year over year in the first quarter of fiscal 2025 (ended September 2024).The company is also witnessing several positive trends in its key end markets that hold promise for its long-term growth. This includes an increase in U.S. and international defense spending volumes an ...

Core Viewpoint - Kennametal Inc. is positioned for growth due to strong performance in its Infrastructure segment and shareholder-friendly policies [1][4][6] Company Overview - Kennametal, based in Latrobe, PA, manufactures and distributes high-speed metal cutting tools, tooling systems, and wear-resistant parts, serving various end markets including aerospace, transportation, and energy [2] Business Strength - The Infrastructure segment is performing well, driven by increased demand in aerospace & defense and energy markets, despite softness in other areas [4] - Positive trends in key markets include rising U.S. and international defense spending and digitalization [4] Product Development - The company benefits from a diversified portfolio and ongoing investments in product development, with notable new products introduced [5] - A new metal cutting inserts manufacturing facility was established in Bengaluru, India, to meet growing demand [5] Shareholder Policies - Kennametal is committed to rewarding shareholders through dividends and share buybacks, distributing $15.6 million in dividends and repurchasing $15 million in shares in Q1 of fiscal 2025 [6] - In fiscal 2024, the company distributed $63.4 million in dividends and repurchased $65.4 million in shares [6] Segmental Weakness - The Metal Cutting segment is experiencing revenue declines due to decreased demand in the transportation market and lower project activity in general engineering [7] - Revenue expectations for fiscal 2025 are projected to be between $2.0 billion and $2.1 billion, indicating a year-over-year decrease of 1.4% at the midpoint [7] Cost Challenges - Kennametal faces high operating expenses, with operating expenses as a percentage of total revenues rising to 23.2% [8] - The operating margin decreased by 130 basis points in Q1 of fiscal 2025 due to higher wages and inflationary pressures [9]

Kennametal Inc. (KMT) is benefiting from the strong performance of the Infrastructure segment, driven by strength in the aerospace & defense and energy end markets arising from favorable order timing. The segment’s revenues increased 0.4% year over year in the first quarter of fiscal 2025 (ended September 2024). Despite the ongoing softness across the majority of end markets, the company is witnessing several positive trends in its key end markets that hold promise for its long-term growth. This includes an ...

Core Insights - The FDA has approved Revuforj® (revumenib) as the first menin inhibitor for treating relapsed or refractory acute leukemia with a KMT2A translocation in patients aged one year and older [1][2][3] - The approval is based on positive data from the AUGMENT-101 clinical trial, demonstrating a 21% complete remission rate among treated patients [2][3] - Syndax Pharmaceuticals is preparing to launch Revuforj and is committed to advancing its development for KMT2A-rearranged acute leukemias and mutant NPM1 AML [2][8] Efficacy and Safety - In the AUGMENT-101 trial, 104 patients were evaluated, with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 21% [2] - The median duration of CR+CRh was 6.4 months, and the median time to CR or CRh was 1.9 months [2] - The safety evaluation involved 135 patients, with common adverse reactions including hemorrhage (53%), nausea (51%), and infection (41%) [3][18] Market Availability - Revuforj tablets (110 mg and 160 mg) are expected to be available for order in the U.S. in November 2024, with 25 mg tablets anticipated in early 2025 [4] - An oral solution of revumenib will be available through an expanded access program for patients weighing less than 40 kg prior to the commercial availability of the 25 mg tablets [4] Company Commitment - Syndax has established SyndAccess™, a program providing personalized support and financial assistance to U.S. patients prescribed Revuforj [5] - The company is focused on removing barriers to access for patients and enhancing support resources [5] Future Developments - Revumenib is also in development for treating R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1), with ongoing trials in combination with standard-of-care agents [8][9] - The company is conducting multiple clinical trials across the treatment landscape for KMT2A-rearranged acute leukemia and mNPM1 AML [8][22]

PITTSBURGH, Nov. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) is proud to announce that it has been recognized as one of Caterpillar Inc's top indirect suppliers in 2024. This prestigious recognition reflects Kennametal's continued dedication to delivering innovative solutions, productivity improvements and outstanding customer and applications engineering support. Key drivers of this recognition include Kennametal's exceptional support in the successful launch of the Cat C27B and C32 cylinder head ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

PITTSBURGH, Nov. 12, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the UBS Global Industrials and Transportation Conference in Manalapan, Florida.Details of the conference are as follows:             When:      Tuesday, December 3, 2024             Attendees: Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations About KennametalWith over 85 years as an industrial technology leader, Kennametal In ...

Kennametal Inc. (KMT) reported first-quarter fiscal 2025 (ended Sept. 30, 2024) adjusted earnings of 29 cents per share, which beat the Zacks Consensus Estimate of 25 cents. The bottom line decreased 29.3% from the year-ago figure.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.KMT’s Revenue DetailsKennametal’s revenues were $481.9 million, which decreased 2% from the year-ago quarter’s figure. Organic sales declined 2% year over year. Business days had a positive impact of 1%. Curr ...